 |
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2019, vol. 25, issue3
Subject Area: Dental Medicine
-
DOI: 10.5272/jimab.2019253.2617
Published online: 22 July 2019
Original article
J of IMAB. 2019 Jul-Sep;25(3):2617-2621;
BISPHOSPHONATE–RELATED OSTEONECROSIS OF THE JAW A 3-YEARS RETROSPECTIVE STUDY OF FREQUENCY AND RISK FACTORS
Rosen Tsolov1
, Elena Firkova2, Ivan Chenchev3, Georgi Jordanov4, Stefka Paecheva5,
1) Department of Maxillo-facial and Oral surgery, Saint George Hospital University Medical Center, Plovdiv, Bulgaria.
2) Department of Periodontology and Oral Diseases, Faculty of Dental Medicine, Medical University – Plovdiv, Bulgaria.
3) Department of Oral Surgery, Faculty of Dental Medicine, Medical University – Plovdiv, Bulgaria.
4) Department of Radiology, Dental Allergology and Physiotherapy”, Faculty of Dental Medicine, Medical University – Plovdiv, Bulgaria.
5)Department of Periodontology and Oral Diseases, Faculty of Dental Medicine, Medical University – Plovdiv, Bulgaria.
ABSTRACT:
Purpose: To estimate the frequency of bisphosphonate-related osteonecrosis (BRONJ) in the Bulgarian population between 2015-2018 and the correlation with the type of bisphosphonates as risk factors associated with BRONJ development.
Materials and methods: A retrospective analysis of the official database from the national health insurance system was conducted. The total number of patients with developed BRONJ was estimated. The type of intravenous bisphosphonate administered was associated with the incidence of BRONJ.
Results: 3543 patients developed BRONJ during 2015 – 2018. The frequency of the condition is constantly increasing. The incidence of BRONJ among patients receiving ibandronate acid was significantly higher than patients on alendronic acid treatment (p <0.001).
Conclusions: BRONJ is constantly increasing condition in the Bulgarian population among cancer patients, treated with intravenous bisphosphonates. Administration of Ibandronic acid can be used as a significant risk factor and a predictor for BRONJ development in those patients.
Keywords: Bisphosphonates, osteonecrosis, incidence, risk,
- Download FULL TEXT /PDF 1178 KB/
Please cite this article as: Tsolov R, Firkova E, Chenchev I, Yordanov G, Paecheva S. Bisphosphonate–related osteonecrosis of the jaw a 3-years retrospective study of frequency and risk factors. J of IMAB. 2019 Jul-Sep;25(3):2617-2621. DOI: 10.5272/jimab.2019253.2617
Correspondence to: Rosen Tsolov, Department of Maxillo-facial and Oral surgery, Saint George Hospital University Medical Center; 66, Peshtersko Shose blvd., Plovdiv, Bulgaria; E-mail: dr.rosentsolov@gmail.com
REFERENCES:
1. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg. 2009 May;67(5 Suppl):2-12. [PubMed] [Crossref]
2. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115–1117.
3. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. Medication-Related Osteonecrosis of the Jaw -- 2014 Update. Position paper. American Association of Oral and Maxillofacial Surgeons. [Internet]
4. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56. [PubMed] [Crossref]
5. Qi WX, Tang LN, He AN, Yao Y, Shen Z. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol. 2014 Apr;19(2):403-10. [PubMed]
6. Coleman R, Woodward E, Brown J, Cameron D, Bell R, Dodwell D. et al: Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. Breast Cancer Res Treat. 2011;127(2):429 – 438.
7. Mauri D, Valachis A, Polyzos IP, Polyzos NP, Kamposioras K, Pesce LL. Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis. Breast Cancer Res Treat. 2009, 116(3):433 – 439.
8. Bamias A, Kastritis E, Bamia C, Moulopoulos I, Bozas G, Koutsoukou V et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005;23:8580–7
9. Yamazaki T, Yamori M, Ishizaki T, Asai K, Goto K, Takahashi K, et al. Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. Int J Oral Maxillofac Surg. 2012 Nov;41(11):1397-403. [PubMed]
10. Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg. 2007;65:1328–31.
11. Kos M. Incidence and risk predictors for osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. Arch Med Sci. 2015 Apr 25;11(2):319-24. [PubMed] [Crossref]
12. Khosla S, Burr, D. Cauley J, Dempster DW, Ebeling PR, Felsenberg D et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007 Oct;22(10):1479-91.
13. Zervas K, Verrou E, Teleioudis Z, Vahtsevanous K, Banti A, Mihou D et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol. 2006;134:20–3.
14. Hoff AO, Toth B, Hu M, Hortobagyi GN, Gagel RF. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann N Y Acad Sci. 2011;1218:47–54.
15. Hoff A, Toth B, Altundag K, Johnson M, Warneke C, Hu m et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphoshonates. J Bone Min Res. 2008;23:826-836.
Received: 12 February 2019
Published online: 22 July 2019